1. AstraZeneca. A randomised, double-blind, placebo-controlled, multicentre phase iii study of olaparib plus abiraterone relative to placebo plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer (PROpel study). clinicaltrials.gov; 2023.
2. Janssen Research & Development, LLC. A phase 3 randomized, placebo-controlled, double-blind study of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in subjects with metastatic prostate cancer. clinicaltrials.gov; 2023.
3. Pfizer. A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer. clinicaltrials.gov; 2023.
4. ASCO Daily News. Clinical News from the American Society of Clinical Oncology. TALAPRO-2 supports first-line talazoparib/enzalutamide in all-comers with mCRPC. 2023. https://dailynews.ascopubs.org/do/talapro-2-supports-first-line-talazoparib-enzalutamide-all-comers-mcrpc.
5. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial;Chi;Ann Oncol,2023